SG49743A1 - Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes - Google Patents

Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes

Info

Publication number
SG49743A1
SG49743A1 SG1996004634A SG1996004634A SG49743A1 SG 49743 A1 SG49743 A1 SG 49743A1 SG 1996004634 A SG1996004634 A SG 1996004634A SG 1996004634 A SG1996004634 A SG 1996004634A SG 49743 A1 SG49743 A1 SG 49743A1
Authority
SG
Singapore
Prior art keywords
lymphocytes
humans
induction
synthetic peptide
peptide epitopes
Prior art date
Application number
SG1996004634A
Other languages
English (en)
Inventor
Ralph T Kubo
Howard M Grey
Alessandro Sette
Esteban Celis
Original Assignee
Cytel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22684274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG49743(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytel Corp filed Critical Cytel Corp
Publication of SG49743A1 publication Critical patent/SG49743A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG1996004634A 1994-01-25 1995-01-25 Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes SG49743A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/186,266 US5662907A (en) 1992-08-07 1994-01-25 Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes

Publications (1)

Publication Number Publication Date
SG49743A1 true SG49743A1 (en) 1998-06-15

Family

ID=22684274

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996004634A SG49743A1 (en) 1994-01-25 1995-01-25 Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes

Country Status (8)

Country Link
US (1) US5662907A (fr)
EP (1) EP0749315A4 (fr)
AU (1) AU1834095A (fr)
CA (1) CA2181920A1 (fr)
MX (1) MX9603007A (fr)
NZ (1) NZ281409A (fr)
SG (1) SG49743A1 (fr)
WO (1) WO1995019783A1 (fr)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US20030152580A1 (en) * 1994-07-21 2003-08-14 Alessandro Sette Hla binding peptides and their uses
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US20110097352A9 (en) * 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US9340577B2 (en) * 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US9266930B1 (en) * 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
US6410022B1 (en) * 1995-05-01 2002-06-25 Avant Immunotherapeutics, Inc. Modulation of cholesteryl ester transfer protein (CETP) activity
US5853719A (en) * 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US7888100B2 (en) * 1996-10-03 2011-02-15 Memorial Sloan-Kettering Cancer Research Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein
US6465251B1 (en) * 1996-11-13 2002-10-15 Dana-Farber Cancer Institute, Inc. Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin
US6087441A (en) * 1997-02-05 2000-07-11 Ludwig Institute For Cancer Research Structurally modified peptides that are resistant to peptidase degradation
WO1998058951A1 (fr) * 1997-06-23 1998-12-30 Ludwig Institute For Cancer Research Nonapeptides et decapeptides isoles se fixant a des molecules hla, et leur utilisation
US6821516B1 (en) * 1997-07-18 2004-11-23 I.D.M. Immuno-Designed Molecules Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
US6548296B1 (en) 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US5965535A (en) * 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
JP2002507387A (ja) * 1997-12-24 2002-03-12 コリクサ コーポレイション 乳癌の免疫療法および診断のための化合物ならびにそれらの使用のための方法
US6379951B1 (en) 1997-12-24 2002-04-30 Corixa Corporation Compounds for immunotherapy of breast cancer and methods for their use
US6410507B1 (en) * 1997-12-24 2002-06-25 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
US6432707B1 (en) 1997-12-24 2002-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6080399A (en) 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma
CA2685270C (fr) * 1998-05-13 2014-07-29 Pharmexa Inc. Vecteurs d'expression destines a stimuler une reponse immunitaire et procedes de leur utilisation
US7264965B2 (en) * 1998-06-05 2007-09-04 Alexis Biotech Limited Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
US20020051783A1 (en) * 1998-06-05 2002-05-02 Savage Philip Michael Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
US7521197B2 (en) * 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
CA2341642C (fr) 1998-09-01 2011-05-24 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Page-4, gene du type gage lie a l'x exprime dans la prostate, les testicules et l'uterus normaux et neoplasiques et utilisation dudit gene
US6468758B1 (en) 1998-09-23 2002-10-22 Corixa Corporation Compositions and methods for ovarian cancer therapy and diagnosis
US20070020327A1 (en) * 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
AU2016199A (en) * 1998-12-24 2000-07-31 New York Medical College Peptide mimics useful for treating disease
WO2002019986A1 (fr) * 2000-09-08 2002-03-14 Epimmune Inc. Induction de reponses immunitaires cellulaires vis-a-vis du virus de l'hepatite b, par des compositions de peptides et d'acides nucleiques
IT1309584B1 (it) * 1999-02-26 2002-01-24 San Raffaele Centro Fond Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso.
US6190670B1 (en) * 1999-04-12 2001-02-20 Immtech International Inc. Use of mCRP to enhance immune responses
IT1312568B1 (it) * 1999-05-21 2002-04-22 Genera Spa Peptidi immunogenici e loro uso.
KR20030000011A (ko) * 1999-05-25 2003-01-03 휴먼 게놈 사이언시즈, 인크. Ｍｅｔｈ－１ 및 ｍｅｔｈ－２ 폴리뉴클레오티드 및폴리펩티드
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
JP2003509465A (ja) * 1999-07-19 2003-03-11 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、ｃ型肝炎ウイルスに対する細胞性免疫応答の誘導
WO2001023577A2 (fr) * 1999-09-30 2001-04-05 Institut Pasteur Polynucleotides hybrides ou chimeriques, proteines et compositions comprenant des sequences du virus de l'hepatite b
US6897288B1 (en) * 1999-10-19 2005-05-24 Ludwig Institute For Cancer Research Mage-A12 antigenic peptides and uses thereof
WO2001036452A2 (fr) * 1999-11-18 2001-05-25 Epimmune Inc. Analogues heteroclites et procedes associes
EP1248800A2 (fr) 1999-11-30 2002-10-16 Corixa Corporation Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
US20040048790A1 (en) * 1999-12-10 2004-03-11 John Fikes Inducing cellular immune responses to p53 using peptide and nucleic acid compositions
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
EP1235841A4 (fr) * 1999-12-10 2006-04-12 Epimmune Inc Declenchement de reponses immunitaires cellulaires a mage2/3 au moyen de compositions de peptides et d'acides nucleiques
US20070098776A1 (en) * 1999-12-13 2007-05-03 Fikes John D HLA class I A2 tumor associated antigen peptides and vaccine compositions
US20040037843A1 (en) * 1999-12-21 2004-02-26 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP1118860A1 (fr) * 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Méthodes pour sélectionner et produire des épitopes peptidiques de cellules T ainsi que des vaccines comprenant lesdits épitopes sélectionnés
AU5810201A (en) * 2000-05-10 2001-11-20 Aventis Pasteur Immunogenic polypeptides encoded by mage minigenes and uses thereof
EP2295578A3 (fr) 2000-10-31 2011-07-06 Eisai Inc. Acides nucléiques Cyp1b1 et leurs procédés d'utilisation
US20040121946A9 (en) * 2000-12-11 2004-06-24 John Fikes Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
EP1353686A4 (fr) * 2000-12-13 2004-04-07 Argonex Pharmaceuticals Peptides associes a la classe i du complexe majeur d'histocompatibilite et utiles dans la prevention et le traitement de la tuberculose
EP2016930B1 (fr) * 2001-02-20 2014-10-15 Janssen Pharmaceuticals, Inc. Suspension des cellules CD8 pour l'utilisation dans le traitement des mélanomes
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
US20040202654A1 (en) 2001-04-09 2004-10-14 Mayo Foundation For Medical Education & Research Methods and materials for cancer treatment
WO2002092120A1 (fr) * 2001-05-15 2002-11-21 Ludwig Institute For Cancer Research Peptides structurellement modifies et leurs utilisations
WO2002094994A2 (fr) * 2001-05-18 2002-11-28 Mayo Foundation For Medical Education And Research Polypeptides chimeres specifiques d'antigene activant des lymphocytes t
US20060222656A1 (en) * 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
CN1511040A (zh) * 2001-05-25 2004-07-07 ����˹���ѷ��ѧ 作为多种治疗模式基础的蛋白质的选择性剪接形式
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
US7422751B2 (en) * 2002-06-14 2008-09-09 Mayo Foundation For Medical Education And Research Epstein-barr-virus-specific immunization
WO2004027041A2 (fr) 2002-09-19 2004-04-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polypeptides p. ariasi, polypeptides p. perniciosus et methodes d'utilisation
AU2003287267A1 (en) 2002-10-29 2004-05-25 Centro De Pesquisas Goncalo Moniz Lutzomyia longipalpis polypeptides and methods of use
CA2520768A1 (fr) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Procedes d'identification de variants optimaux d'epitopes peptidiques
US20050249743A1 (en) * 2004-01-12 2005-11-10 Thierry Boon-Falleur Isolated peptides which bind to HLA-A24 molecules and uses thereof
WO2005115447A2 (fr) * 2004-05-25 2005-12-08 The Trustees Of The University Of Pennsylvania Immunotherapie anticancereuse humaine
CA2566506A1 (fr) * 2004-06-01 2005-12-15 Innogenetics N.V. Peptides destines a induire une reponse ctl et/ou htl au virus de l'hepatite c
KR20100092031A (ko) * 2004-06-17 2010-08-19 맨카인드 코포레이션 에피토프 유사체
DE102004049223A1 (de) * 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
WO2008039171A2 (fr) * 2005-08-08 2008-04-03 Oregon Health & Science University Inactivation d'agents pathogènes avec du peroxyde d'hydrogène pour la production de vaccin
WO2007106536A2 (fr) 2006-03-14 2007-09-20 Oregon Health & Science University Procédés pour induire une réponse immunitaire à la tuberculose
WO2007105954A1 (fr) * 2006-03-16 2007-09-20 Leiden University Medical Center Procédés d'identification d'épitopes de lymphocytes t associés à une compromission de la transformation de peptides et applications des épitopes identifiés
WO2008053573A1 (fr) 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remède pour néoplasme malin
EP2125868B1 (fr) 2007-02-28 2015-06-10 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Polypeptides brachyury et procédés d'utilisation
US20090117123A1 (en) * 2007-11-02 2009-05-07 National Health Research Institutes Immunopeptides of hpv e6 and e7 proteins
SG188907A1 (en) 2008-03-31 2013-04-30 Bioimmulance Co Ltd Partial peptide of survivin presented on mhc class ii molecule and use thereof
EP2391635B1 (fr) 2009-01-28 2017-04-26 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations
WO2010088393A2 (fr) * 2009-01-28 2010-08-05 Antigen Express, Inc. Peptides hybrides li-key modulant la réponse immunitaire à la grippe
WO2010099472A2 (fr) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Polypeptides spanx-b et leur utilisation
WO2011041886A1 (fr) 2009-10-07 2011-04-14 University Of Victoria Innovation And Development Corporation Vaccins comprenant des transgènes thermosensibles
EP3263124A1 (fr) 2009-11-20 2018-01-03 Oregon Health&Science University Procédés de génération de réponse immunitaire à la tuberculose
WO2011112599A2 (fr) 2010-03-12 2011-09-15 The United States Of America, As Represented By The Secretary. Department Of Health & Human Services Peptides pote immunogènes et leurs procédés d'utilisation
CA2811103C (fr) 2010-09-14 2020-01-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Antigenes contre la grippe a reactivite large optimises par ordinateur
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
JP6113155B2 (ja) 2011-06-20 2017-04-12 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原
EP2753642B8 (fr) 2011-09-06 2017-12-13 Novo Nordisk A/S Dérivés de glp-1
CN109517055B (zh) 2011-09-15 2022-09-20 美国卫生和人力服务部 识别hla-a1-或hla-cw7-限制的mage的t细胞受体
RU2653756C2 (ru) 2012-02-07 2018-05-14 Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2
WO2013122827A1 (fr) 2012-02-13 2013-08-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Antigènes largement réactifs optimisés par ordinateur pour la grippe h5n1 humaine et aviaire
US20150224181A1 (en) 2012-09-14 2015-08-13 The United States Of America As Represented By The Secretary Department Of Health And Human Se Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
DK3079716T3 (da) 2013-12-13 2019-08-19 Us Health Multiepitop-tarp-peptidvaccine og anvendelser deraf.
US10253075B2 (en) 2014-02-26 2019-04-09 tella, Inc. WT1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
US10117922B2 (en) 2014-05-13 2018-11-06 Emergex Vaccines Holding Ltd. Dengue virus specific multiple HLA binding T cell epitopes for the use of universal vaccine development
JP6811706B2 (ja) 2014-07-31 2021-01-13 ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー Ｅｐｈａ４に対するヒトモノクローナル抗体及びそれらの使用
US10550164B2 (en) 2015-08-03 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding Brachyury deletion mutants, and their use
CN105037559B (zh) * 2015-08-17 2018-09-25 北京康爱瑞浩生物科技股份有限公司 治疗或预防乙肝的细胞毒性t淋巴细胞及其制备方法
CN109069575A (zh) * 2016-02-23 2018-12-21 毛里齐奥·扎内蒂 通用癌症疫苗
AU2017261705B2 (en) 2016-05-10 2024-04-18 Najit Technologies, Inc. Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
US20180161433A1 (en) * 2017-03-22 2018-06-14 Timothy Andrew Erickson Size tunable microbial mimetics for immunotherapy of thyroid carcinomas and solid tumors
PE20191842A1 (es) 2017-05-08 2019-12-31 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus
KR20200115689A (ko) * 2017-12-28 2020-10-07 그릿스톤 온콜로지, 인코포레이티드 공통 항원을 표적화하는 항원-결합 단백질
EP3735271A4 (fr) 2018-01-04 2022-06-15 Iconic Therapeutics, Inc. Anticorps anti-facteur tissulaire, conjugués anticorps-médicament et procédés associés
US11344614B2 (en) 2018-09-29 2022-05-31 Emergex Vaccines Holding Ltd. Pharmaceutical compositions comprising dengue virus-specific multiple HLA-binding T cell epitopes
TW202110870A (zh) 2019-05-30 2021-03-16 美商葛利史東腫瘤科技公司 經修飾之腺病毒
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
FR3119325B1 (fr) 2021-01-29 2023-08-11 Renault Jean Yves Compositions liposomales orales

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200320A (en) * 1987-12-07 1993-04-06 National Jewish Center For Immunology And Respiratory Medicine Method for identifying useful polypeptide vaccines
ES2055785T3 (es) * 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
SG52492A1 (en) * 1992-08-07 1998-09-28 Cytel Corp Hla binding peptides and their uses
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
ES2225824T3 (es) * 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
CA2168950A1 (fr) * 1993-08-06 1995-02-16 Esteban Celis Methodes pour therapie ex vivo, utilisant des antigenes charges de peptides, avec presentation de cellules pour l'activation des ctl
WO1995028958A1 (fr) * 1994-04-22 1995-11-02 Sloan-Kettering Institute For Cancer Research Induction de lymphocytes t cytotoxiques obtenue en utilisant des peptides antigeniques et un adjuvant approprie

Also Published As

Publication number Publication date
EP0749315A4 (fr) 2000-01-05
MX9603007A (es) 1998-05-31
NZ281409A (en) 2000-01-28
AU1834095A (en) 1995-08-08
US5662907A (en) 1997-09-02
CA2181920A1 (fr) 1995-07-27
WO1995019783A1 (fr) 1995-07-27
EP0749315A1 (fr) 1996-12-27

Similar Documents

Publication Publication Date Title
SG49743A1 (en) Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
PL320612A1 (en) Induction of response of t cytotoxic lymphocytes
GB9206757D0 (en) Novel peptide receptor ligands
GB9221654D0 (en) Recombinant human anti-cytomegalovirus antibodies
HUP9801746A3 (en) Lymphotoxin-alfa/beta complexes and anti-lymphotoxin-beta receptor antibodies as anti-tumor agents
GB2263396B (en) Seats
IL116658A0 (en) Peptides their preparation and use
PL299367A1 (en) Linear peptides
EP0935608A4 (fr) Peptides cytotoxiques
GB2269987B (en) Seat
GB9200021D0 (en) Seating
GB2301620B (en) Seats
GB9010740D0 (en) Peptide compounds and their preparation
GB2271278B (en) Concept in seating
GB9106568D0 (en) Recombinant antigen
GB9201032D0 (en) Composite seat
GB9203027D0 (en) Particulate composite material
GB9213660D0 (en) Seat belt cover
AU116725S (en) Seat belt cover
GB9200055D0 (en) Modified seat belt
GB9216225D0 (en) Seat belt
GB2270467B (en) Seating
GB9508569D0 (en) Particulate composite material
GB2266658B (en) Seat
GB9226074D0 (en) Peptide